Prescrire IN ENGLISH - HOME

Register online | Log in | My Prescrire

Issue contents

About Prescrire

english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Spotlight

100 most recent
Archives

No regard for patients!

Editorial Risperidone for monthly injection (Okedi°) was granted marketing authorisation on the basis of a randomised placebo-controlled trial in patients experiencing an acute exacerbation of schizophrenia (see “Risperidone as monthly injections” Prescrire Int n° 252 > Subscribers only). This placebo-controlled trial was doubly disgraceful.

1 October 2023

Rimegepant (Vydura°) in migraine

Marketing Authorisations Rimegepant is another CGRP receptor antagonist, with a chemical structure completely different from that of the monoclonal antibodies initially available. It is the first CGRP inhibitor to be authorised in the European Union for oral administration, both for the treatment and prevention of migraine attacks.
Full article (4 pages) available for download by subscribers

1 October 2023

Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection

Marketing Authorisations Lenacapavir is an antiretroviral drug that binds to the HIV-1 capsid. This disrupts various steps in the HIV lifecycle in which the capsid plays a role, such as transport of the viral genome into the nucleus of an infected cell, integration of the viral genome, and assembly of various viral components. It is the first antiretroviral with this mechanism of action to have been authorised in the European Union.
Full article (3 pages) available for download by subscribers

1 October 2023

Cannabidiol: sometimes serious adverse effects, and multiple drug interactions

Adverse Effects Cannabidiol (CBD), a cannabinoid, is naturally present in cannabis. Cannabidiol is used as an antiepileptic. Some CBD-containing products are sold without the regulatory status of medicines, and sometimes also contain other cannabinoids.
Full article (1 page) available for download by subscribers

1 October 2023

Drug shortages: patients lose out, healthcare professionals waste time

Outlook Drug shortages expose patients to a risk of serious, sometimes fatal, adverse effects, medication errors, and worsening of their disease. In daily practice, the workload of healthcare professionals is increased, with harmful consequences for the healthcare system, exacerbating an already fragile situation. In 2020-21, using the French pharmacovigilance database, France’s regional pharmacovigilance centres (CRPV) carried out a study on the consequences of drug shortages.
Full article (2 pages) available for download by subscribers

1 October 2023

Prescrire: a cosignatory of letters to various European institutions

Advancing Healthcare Policy In late 2022, Prescrire was a cosignatory of letters to three institutions in Europe: the Council of the European Union, the European Patent Office, and the European Parliament's Special Committee tasked with evaluating the handling of the covid-19 pandemic.

1 October 2023

Publication of clinical trial protocols

Advancing Healthcare Policy In a joint letter to the European Medicines Agency's Management Board, Prescrire contested an Agency plan that would delay publication of the protocols of drug trials.

1 October 2023

Practicalities

Editorial A drug is more than just an active substance mixed with excipients. There is more to consider than its pharmacological properties or its economic success. A drug is also a physical product that is part of the patient's daily life. And its packaging components, such as its box, the blister packs, bottle, vial or syringe, and the patient leaflet, are an integral part of this.

1 September 2023

Nivolumab (Opdivo°) in advanced gastric or oesophageal cancer

Marketing Authorisations Nivolumab, a monoclonal antibody directed against PD-1, has been authorised for patients with metastatic or inoperable gastric or oesophageal adenocarcinoma or squamous cell carcinoma. In these situations, does nivolumab represent a therapeutic advance compared to the treatments already available, and, in particular, does it extend survival?
Full article (3 pages) available for download by subscribers

1 September 2023

Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer

Adverse Effects In 2022, a French research team published a case-control study which investigated the association between exposure to a GLP-1 receptor agonist and the risk of developing thyroid cancer.
Full article available for download by subscribers

1 September 2023

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90